LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

Search

Revvity Inc

Abierto

SectorSalud

92.23 -2.17

Resumen

Variación precio

24h

Actual

Mínimo

91.35

Máximo

94.25

Métricas clave

By Trading Economics

Ingresos

-52M

42M

Ventas

-65M

665M

P/B

Media del Sector

38.519

54.379

BPA

1.01

Rentabilidad por dividendo

0.3

Margen de beneficio

6.354

Empleados

11,000

EBITDA

-151M

72M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+28.92% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.30%

2.55%

Próximas Ganancias

28 jul 2025

Fecha Próximo Dividendo

9 may 2025

Próxima Fecha de Ex Dividendo

18 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-2.8B

11B

Apertura anterior

94.4

Cierre anterior

92.23

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

134 / 382 Clasificación en Healthcare

Revvity Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 may 2025, 23:59 UTC

Principales Noticias
Ganancias

Naver 1Q Net Slumps on Higher Costs

8 may 2025, 23:39 UTC

Ganancias

OCBC 1Q Net Down on Lower Interest Income

8 may 2025, 23:01 UTC

Ganancias

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 may 2025, 22:52 UTC

Ganancias

REA Expects Annual Listings Growth Despite April Decline

8 may 2025, 22:46 UTC

Ganancias

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 may 2025, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 may 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 may 2025, 23:41 UTC

Charlas de Mercado

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 may 2025, 23:30 UTC

Ganancias

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 may 2025, 23:29 UTC

Ganancias

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 may 2025, 23:22 UTC

Ganancias

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 may 2025, 23:22 UTC

Ganancias

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 may 2025, 23:21 UTC

Ganancias

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 may 2025, 23:21 UTC

Ganancias

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 may 2025, 23:17 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 may 2025, 23:17 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 may 2025, 23:17 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 may 2025, 23:05 UTC

Charlas de Mercado

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 may 2025, 23:05 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 may 2025, 23:01 UTC

Principales Noticias

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 may 2025, 22:28 UTC

Ganancias

REA Expects FY 2025 Listings Growth of 1-2%

8 may 2025, 22:28 UTC

Ganancias

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 may 2025, 22:27 UTC

Ganancias

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 may 2025, 22:27 UTC

Ganancias

REA Says April Residential Listings Fell by 11% on Year

8 may 2025, 22:26 UTC

Ganancias

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 may 2025, 22:26 UTC

Ganancias

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 may 2025, 22:26 UTC

Ganancias

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 may 2025, 22:26 UTC

Ganancias

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 may 2025, 22:25 UTC

Ganancias

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 may 2025, 22:25 UTC

Ganancias

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Comparación entre iguales

Cambio de precio

Revvity Inc Esperado

Precio Objetivo

By TipRanks

28.92% repunte

Estimación a 12 meses

Media 118.08 USD  28.92%

Máximo 135 USD

Mínimo 100 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Revvity Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

9

Comprar

5

Mantener

0

Vender

Sentimiento

By Acuity

134 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.